HUMA – humacyte, inc. (US:NASDAQ)
Stock Stats
News
Humacyte (NASDAQ:HUMA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $25.00 price target on the stock.
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair [Yahoo! Finance]
Humacyte Announces Publication of Long-Term Safety and Efficacy Results of Symvess® in Extremity Trauma Repair
Humacyte (NASDAQ:HUMA) was downgraded by analysts at Wall Street Zen
Humacyte (NASDAQ:HUMA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Form 8-K Humacyte, Inc. For: Dec 16
Form 424B5 Humacyte, Inc.
Form 8-K Humacyte, Inc. For: Dec 15
Form 8-K Humacyte, Inc. For: Dec 15
Form 424B3 Humacyte, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.